Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized masked study of bel-sar versus sham in small choroidal melanoma or primary indeterminate lesions
MOH_2024-06-10_013439Phase 3Not yet recruiting
- Sponsor
- Aura Biosciences, Inc
- Start
- May 2024
- Modality
- Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Recombinant Proteins and Enzymes, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of belzupacap sarotalocan in choroidal melanoma and eye lesion (3 arms), sponsored by Aura Biosciences, Inc. Primary endpoint: Primary endpoint not specified. Planned start May 2024; status: not yet recruiting.
02
Drugs
belzupacap sarotalocan
03
Conditions
choroidal melanomaeye lesion
Beyond the preview
Go deeper on MOH_2024-06-10_013439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-06-10_013439.